1. Home
  2. EXFY vs PYXS Comparison

EXFY vs PYXS Comparison

Compare EXFY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.77

Market Cap

156.2M

Sector

Technology

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$2.64

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
PYXS
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
141.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EXFY
PYXS
Price
$1.77
$2.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$4.50
$7.00
AVG Volume (30 Days)
1.5M
1.5M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
$142,101,000.00
$13,858,000.00
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$0.97
52 Week High
$2.26
$5.55

Technical Indicators

Market Signals
Indicator
EXFY
PYXS
Relative Strength Index (RSI) 56.34 56.61
Support Level $1.37 $1.22
Resistance Level $2.02 $2.92
Average True Range (ATR) 0.12 0.29
MACD -0.03 -0.01
Stochastic Oscillator 26.04 48.37

Price Performance

Historical Comparison
EXFY
PYXS

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: